CJC-1295 side effects
The immune question concerns the peptide. Other concerns arise from the growth hormone and IGF-1 that it raises, so the safety record needs several separate entries.
Fluid retention
Growth hormone can make the kidneys retain sodium and expand extracellular fluid volume. Water retention therefore has a physiological basis beyond the accounts of puffy hands and faces. The sodium-retention work concerns growth hormone; it supplies a mechanism relevant to CJC-1295’s hormone stimulation.
Community reports describe swelling and tingling fingers, sometimes compared with carpal tunnel symptoms. These are anecdotal accounts rather than clinical evidence, and fluid pressing on nerves is a plausible explanation rather than an established diagnosis for each report. They supply neither a treated population count nor a measured complication rate.
I take swelling seriously because the mechanism reaches beyond appearance. Assigning CJC-1295 a numerical risk from a study of growth hormone or from the frequency of online complaints would exceed either record.
Insulin sensitivity
Sustained growth-hormone stimulation can reduce insulin sensitivity, meaning that insulin does less effective work controlling blood sugar. A clinical study of a related GHRH analog examined insulin sensitivity alongside hormone pulsatility. It is relevant class evidence, with a different intervention from CJC-1295.
Some community accounts also describe higher blood sugar. The reports are anecdotal; home observations leave causes unresolved. Diabetes, prediabetes and existing insulin resistance make this physiological concern especially consequential. The CJC-1295 studies cannot give an exact rate of deterioration during lasting use.
IGF-1 and cancer associations
Renehan and colleagues’ 2004 systematic review and meta-regression associated higher circulating IGF-1 with modestly increased risk of certain cancers. These were population observations about IGF-1. The participants were not being given CJC-1295 to test whether it caused cancer.
The connection to CJC-1295 begins with its ability to raise IGF-1. In healthy adults receiving repeated experimental administrations, IGF-1 remained above baseline up to 28 days. Prolonged elevation gives a reason to investigate the cancer question, especially in relation to an existing or undiagnosed tumour. The association cannot tell us how much, if at all, CJC-1295 changes cancer risk.
The alarming version of this story outruns the evidence just as readily as the reassuring version. Without treated-human follow-up, I cannot choose between those conclusions.
The stopped development program
The Phase 2 trial in HIV-associated visceral obesity examined CJC-1295 DAC in a particular patient population with excess fat around internal organs. The program was discontinued. A patient's death has been reported during development, though the available evidence doesn't establish that CJC-1295 caused the death.
Attributing the death to CJC-1295 would exceed this record. Nor can an unresolved cause establish safety. The concrete consequence is an unfinished development record, with no approval and no completed long-term human safety program.
The immune-response concern adds another unanswered question. For tested athletes, there is also a clear eligibility issue: WADA prohibits CJC-1295 at all times under Section S2.